Biodesix Receives 'Moderate Buy' Rating from Analysts

The biotech company's stock is covered by six research firms with a consensus recommendation.

Published on Mar. 12, 2026

Got story updates? Submit your updates here. ›

Biodesix, Inc. (NASDAQ:BDSX), a molecular diagnostics company focused on lung diseases, has been assigned a 'Moderate Buy' consensus rating from the six research firms currently covering the stock. One analyst has a 'sell' rating, while five have issued 'buy' recommendations, with an average 12-month price target of $32.50.

Why it matters

Biodesix is a commercial-stage biotech company developing blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The 'Moderate Buy' consensus rating from analysts suggests they see potential upside in the company's stock, which could indicate confidence in Biodesix's product pipeline and business strategy.

The details

The analysts' ratings on Biodesix include a 'sell' rating from Weiss Ratings, while Canaccord Genuity Group and William Blair have issued 'buy' recommendations. William Blair also upgraded the stock from 'market perform' to 'outperform' in late February. In its latest quarterly results, Biodesix reported revenue of $28.76 million, exceeding analysts' expectations of $26.25 million.

  • Biodesix released its Q4 2025 earnings results on February 26, 2026.
  • Weiss Ratings issued a 'sell (e+)' rating on Biodesix on December 22, 2025.
  • Canaccord Genuity Group reiterated a 'buy' rating and $20.00 price target on February 17, 2026.
  • William Blair upgraded Biodesix to 'outperform' on February 27, 2026.

The players

Biodesix, Inc.

A commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer.

Scott Hutton

The CEO of Biodesix.

Jack W. Schuler

A director on Biodesix's board.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The 'Moderate Buy' consensus rating on Biodesix's stock suggests analysts see potential upside in the company's molecular diagnostics business, which could indicate confidence in its product pipeline and strategy as it works to improve the diagnosis and management of lung diseases.